Gene Editing

A special issue of Biomolecules (ISSN 2218-273X).

Deadline for manuscript submissions: closed (29 February 2016)

Special Issue Editor


E-Mail Website
Guest Editor
Gene Editing Institute, Helen F. Graham Cancer Center & Research Institute, ChristianaCare, Newark, DE 19713, USA
Interests: CRISPR/Cas- directed gene eding; small molecules; HDR, NHEJ; regulation of genome editing
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The capability of changing mammalian genes at specific sites within the chromosome has held a certain fascination for geneticists over the last 30 years. With the development of genetic tools such as single-stranded oligonucleotides, Zinc Finger Nucleases, TALENS and CRISPR/Cas9, the possibility of using genome re-engineering techniques with a high degree of precision is now a reality. But which tools, which combination of gene editing technologies, affords the greatest opportunity for success for a particular objective or application? This edition of Biomolecules, with contributions from pioneering groups as well as research groups that are leading the field, will provide answers to these important questions and will not simply be another compilation of review articles that discuss the merits of gene editing technologies. Rather, the outstanding group of authors  will provide sage, experienced advice on how they choose which tools and how to utilize them to achieve the maximum benefit. Case studies with positive and negative outcomes in the decision-making process will be emphasized throughout each article, making this edition a unique yet extremely helpful addition to the gene editing literature.

Prof. Dr. Eric B. Kmiec
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop